Skip to main content
Mike Ehlers

Mike Ehlers

Biotech executive and neuroscientist Michael (Mike) Ehlers, MD, PhD — founding CEO and Board Chair of RNA exon-editing company Ascidian Therapeutics, recently appointed Chief Scientific Officer and Head of R&D at Formation Bio.

Jun 12, 2026

14:02
exon editing in general?
14:06
Yeah, maybe from other forms of RNA editing.
14:08
So I'd say relative to other forms of RNA editing, the short answer is that most RNA editing is like fixing typos.
14:17
And RNA exon editing is rewriting entire sentences.
14:22
So traditional RNA editing like ADAR-based adenosine to inosine editing typically changes single nucleotides.
14:30
And that's powerful for point mutations, but doesn't necessarily scale well to diseases that are caused by large deletions, insertions, or complex mutations.
14:40
So RNA exon editing operates at a different level.
15:44
mike one of the things i always like to ask my guests is where they are what stage they're at with their clinical trials so can you talk to us a little bit about what the city is doing in terms of your clinical trials where we're at where we're headed

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.